Cargando…

The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome

Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Likun, Zhang, Lei, Guo, Yixuan, Xu, Xintong, Liu, Zhaoyun, Yan, Zhenyu, Fu, Rong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767949/
https://www.ncbi.nlm.nih.gov/pubmed/36569863
http://dx.doi.org/10.3389/fimmu.2022.1078421
_version_ 1784854066311987200
author Zheng, Likun
Zhang, Lei
Guo, Yixuan
Xu, Xintong
Liu, Zhaoyun
Yan, Zhenyu
Fu, Rong
author_facet Zheng, Likun
Zhang, Lei
Guo, Yixuan
Xu, Xintong
Liu, Zhaoyun
Yan, Zhenyu
Fu, Rong
author_sort Zheng, Likun
collection PubMed
description Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acute leukemia. Several studies have shown that the BM microenvironment plays a critical role in the progression of MDS. In this study, we specifically evaluated mesenchymal stromal cells (MSCs) that exert immunomodulatory effects in the BM microenvironment. This immunomodulatory effect occurs through direct cell-cell contact and the secretion of soluble cytokines or micro vesicles. Several researchers have compared MSCs derived from healthy donors to low-risk MDS-associated bone mesenchymal stem cells (BM-MSCs) and have found no significant abnormalities in the MDS-MSC phenotype; however, these cells have been observed to exhibit altered function, including a decline in osteoblastic function. This altered function may promote MDS progression. In patients with MDS, especially high-risk patients, MSCs in the BM microenvironment regulate immune cell function, such as that of T cells, B cells, natural killer cells, dendritic cells, neutrophils, myeloid-derived suppressor cells (MDSCs), macrophages, and Treg cells, thereby enabling MDS-associated malignant cells to evade immune cell surveillance. Alterations in MDS-MSC function include genomic instability, microRNA production, histone modification, DNA methylation, and abnormal signal transduction and cytokine secretion.
format Online
Article
Text
id pubmed-9767949
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97679492022-12-22 The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome Zheng, Likun Zhang, Lei Guo, Yixuan Xu, Xintong Liu, Zhaoyun Yan, Zhenyu Fu, Rong Front Immunol Immunology Myelodysplastic syndrome (MDS) is a common hematological malignant disease, characterized by malignant hematopoietic stem cell proliferation in the bone marrow (BM); clinically, it mainly manifests clinically mainly by as pathological hematopoiesis, hemocytopenia, and high-risk transformation to acute leukemia. Several studies have shown that the BM microenvironment plays a critical role in the progression of MDS. In this study, we specifically evaluated mesenchymal stromal cells (MSCs) that exert immunomodulatory effects in the BM microenvironment. This immunomodulatory effect occurs through direct cell-cell contact and the secretion of soluble cytokines or micro vesicles. Several researchers have compared MSCs derived from healthy donors to low-risk MDS-associated bone mesenchymal stem cells (BM-MSCs) and have found no significant abnormalities in the MDS-MSC phenotype; however, these cells have been observed to exhibit altered function, including a decline in osteoblastic function. This altered function may promote MDS progression. In patients with MDS, especially high-risk patients, MSCs in the BM microenvironment regulate immune cell function, such as that of T cells, B cells, natural killer cells, dendritic cells, neutrophils, myeloid-derived suppressor cells (MDSCs), macrophages, and Treg cells, thereby enabling MDS-associated malignant cells to evade immune cell surveillance. Alterations in MDS-MSC function include genomic instability, microRNA production, histone modification, DNA methylation, and abnormal signal transduction and cytokine secretion. Frontiers Media S.A. 2022-12-07 /pmc/articles/PMC9767949/ /pubmed/36569863 http://dx.doi.org/10.3389/fimmu.2022.1078421 Text en Copyright © 2022 Zheng, Zhang, Guo, Xu, Liu, Yan and Fu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zheng, Likun
Zhang, Lei
Guo, Yixuan
Xu, Xintong
Liu, Zhaoyun
Yan, Zhenyu
Fu, Rong
The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
title The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
title_full The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
title_fullStr The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
title_full_unstemmed The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
title_short The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
title_sort immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767949/
https://www.ncbi.nlm.nih.gov/pubmed/36569863
http://dx.doi.org/10.3389/fimmu.2022.1078421
work_keys_str_mv AT zhenglikun theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT zhanglei theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT guoyixuan theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT xuxintong theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT liuzhaoyun theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT yanzhenyu theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT furong theimmunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT zhenglikun immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT zhanglei immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT guoyixuan immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT xuxintong immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT liuzhaoyun immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT yanzhenyu immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome
AT furong immunologicalroleofmesenchymalstromalcellsinpatientswithmyelodysplasticsyndrome